Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected eritrean immigrant

Emerging Infectious Diseases

Volumn 17, Issue 10, 2011, Pages 1966-1968

  Bansal, Vineeta ^a   Metzner, Karin J ^a   Niederöst, Barbara ^a   Leemann, Christine ^a   Böni, Jürg ^b   Günthard, Huldrych F ^a   Fehr, Jan S ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; ERITREA; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMIGRANT; LETTER; MUTATIONAL ANALYSIS; NONHUMAN; SWITZERLAND; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS TRANSMISSION;

EID: 84930482166     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1710.110592     Document Type: Letter

References (7)

1. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-71. doi:10.1016/S1473-3099(11)70032-9
2. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-6.
3. Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis. 2010;201:1063-71. doi:10.1086/651136
4. World Health Organization. Antiretroviral therapy for adults and adolescents: recommendations for a public health approach. 2010 [cited 2010 Dec 27]. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf
5. Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1variants in chronically HIV-1 infected, treatmentnaive patients. J Clin Virol. 2011;50:156-61. doi:10.1016/j.jcv.2010.10.001
6. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, Heneine W, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naïve chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011;203:798-802. doi:10.1093/infdis/jiq126
7. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to firstline highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409-17. doi:10.1016/S1473-3099(09)70136-7